-
Something wrong with this record ?
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
S. Jagannath, S. Delimpasi, S. Grosicki, DR. Van Domelen, OS. Bentur, I. Špička, MA. Dimopoulos
Language English Country United States
Document type Randomized Controlled Trial, Journal Article
- MeSH
- Dexamethasone therapeutic use MeSH
- Quality of Life * MeSH
- Humans MeSH
- Multiple Myeloma * drug therapy MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Drug Tapering MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: Dose modifications in response to adverse events (AEs) can maintain tumor response and improve therapy tolerability. We conducted a post-hoc analysis of the efficacy and safety of reduced selinexor doses in the BOSTON trial (NCT03110562). PATIENTS AND METHODS: Efficacy, safety, and quality of life (QoL) in 195 patients with relapsed/refractory multiple myeloma randomized to once-weekly (QW) selinexor (100 mg), QW subcutaneous bortezomib (1.3 mg/m2), and twice-weekly dexamethasone (20 mg) were compared between patients with dose reductions and those without. RESULTS: In total, 126 patients (65%) had selinexor dose reductions (median dose 71.4 mg/wk). In patients with dose reductions versus those without median progression-free survival was 16.6 months (95% CI 12.9-not evaluable [NE]) versus 9.2 months [95% CI 6.8-15.5]), overall response rate was 81.7% (95% CI 73.9-88.1%) versus 66.7% (95% CI 54.3-77.6%), ≥very good partial response was (51.6% [95% CI 42.5-60.6%] vs. 31.9% [95% CI 21.2-44.2]), median duration of response was not reached (95% CI 13.8-NE) versus 12.0 months (95% CI 8.3-NE), and time to next treatment was 22.6 months (95% CI 14.6-NE) versus 10.5 months (95% CI 6.3-18.2). Mean best change from baseline on the EORTC QLQ-C30 Global Health Status/QoL scale was 10.0 ± 20.5 versus 4.0 ± 20.9. Duration-adjusted AE rates that were lower after selinexor dose reduction included thrombocytopenia (62.5% before vs. 47.6% after), nausea (31.6% vs. 7.3%), fatigue (28.1% vs. 9.9%), decreased appetite (21.5% vs. 6.4%), anemia (17.9% vs. 10.3%), and diarrhea (12.9% vs. 5.2%). CONCLUSION: Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.
Charles University and General Hospital Prague Czech Republic
General Hospital Evangelismos Athens Greece
Karyopharm Therapeutics Inc Newton MA
Medical University of Silesia Katowice Poland
National and Kapodistrian University of Athens School of Medicine Athens Greece
Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York NY
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000470
- 003
- CZ-PrNML
- 005
- 20240213093212.0
- 007
- ta
- 008
- 240109s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clml.2023.08.018 $2 doi
- 035 __
- $a (PubMed)37743180
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jagannath, Sundar $u Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Sundar.jagannath@mountsinai.org
- 245 10
- $a Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study / $c S. Jagannath, S. Delimpasi, S. Grosicki, DR. Van Domelen, OS. Bentur, I. Špička, MA. Dimopoulos
- 520 9_
- $a BACKGROUND: Dose modifications in response to adverse events (AEs) can maintain tumor response and improve therapy tolerability. We conducted a post-hoc analysis of the efficacy and safety of reduced selinexor doses in the BOSTON trial (NCT03110562). PATIENTS AND METHODS: Efficacy, safety, and quality of life (QoL) in 195 patients with relapsed/refractory multiple myeloma randomized to once-weekly (QW) selinexor (100 mg), QW subcutaneous bortezomib (1.3 mg/m2), and twice-weekly dexamethasone (20 mg) were compared between patients with dose reductions and those without. RESULTS: In total, 126 patients (65%) had selinexor dose reductions (median dose 71.4 mg/wk). In patients with dose reductions versus those without median progression-free survival was 16.6 months (95% CI 12.9-not evaluable [NE]) versus 9.2 months [95% CI 6.8-15.5]), overall response rate was 81.7% (95% CI 73.9-88.1%) versus 66.7% (95% CI 54.3-77.6%), ≥very good partial response was (51.6% [95% CI 42.5-60.6%] vs. 31.9% [95% CI 21.2-44.2]), median duration of response was not reached (95% CI 13.8-NE) versus 12.0 months (95% CI 8.3-NE), and time to next treatment was 22.6 months (95% CI 14.6-NE) versus 10.5 months (95% CI 6.3-18.2). Mean best change from baseline on the EORTC QLQ-C30 Global Health Status/QoL scale was 10.0 ± 20.5 versus 4.0 ± 20.9. Duration-adjusted AE rates that were lower after selinexor dose reduction included thrombocytopenia (62.5% before vs. 47.6% after), nausea (31.6% vs. 7.3%), fatigue (28.1% vs. 9.9%), decreased appetite (21.5% vs. 6.4%), anemia (17.9% vs. 10.3%), and diarrhea (12.9% vs. 5.2%). CONCLUSION: Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kvalita života $7 D011788
- 650 _2
- $a vysazování léků $7 D000084862
- 650 _2
- $a dexamethason $x terapeutické užití $7 D003907
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 12
- $a mnohočetný myelom $x farmakoterapie $7 D009101
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Delimpasi, Sosana $u General Hospital Evangelismos, Athens, Greece
- 700 1_
- $a Grosicki, Sebastian $u Medical University of Silesia, Katowice, Poland
- 700 1_
- $a Van Domelen, Dane R $u Karyopharm Therapeutics Inc., Newton, MA
- 700 1_
- $a Bentur, Ohad S $u Karyopharm Therapeutics Inc., Newton, MA
- 700 1_
- $a Špička, Ivan $u Charles University and General Hospital, Prague, Czech Republic
- 700 1_
- $a Dimopoulos, Meletios A $u National and Kapodistrian University of Athens School of Medicine, Athens, Greece
- 773 0_
- $w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 23, č. 12 (2023), s. 917-923.e3
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37743180 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093209 $b ABA008
- 999 __
- $a ok $b bmc $g 2049247 $s 1210164
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 23 $c 12 $d 917-923.e3 $e 20230829 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
- LZP __
- $a Pubmed-20240109
